Latest & greatest articles for breast cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer screening

161. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study.

Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. OBJECTIVE: To investigate whether information on mammographic screening presented on websites by interest groups is balanced, is independent of source of funding, and reflects recent findings. DESIGN: Cross sectional study using a checklist with 17 information items. SETTING: 27 websites in Scandinavian and English speaking countries. RESULTS: The 13 sites from advocacy groups (...) and the 11 from governmental institutions all recommended mammographic screening, whereas the three from consumer organisations questioned screening (P = 0.0007). All the advocacy groups accepted industry funding, apparently without restrictions. In contrast the three consumer organisations acknowledged the risk of bias related to industry funding, and two of them did not accept such funding at all. Advocacy groups and governmental organisations favoured information items that shed positive light

BMJ2004 Full Text: Link to full Text with Trip Pro

162. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer

Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer Kerr J Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kerr J. Review of the effectiveness of infrared thermal imaging (thermography) for population screening and diagnostic testing of breast cancer. Christchurch: New Zealand Health Technology Assessment (NZHTA) 2004: 49 Authors' objectives To review the evidence for the effectiveness of infrared thermography for population screening and diagnostic testing of breast cancer. - Topic

Health Technology Assessment (HTA) Database.2004

163. MRI screening for breast cancer in genetically high-risk women

MRI screening for breast cancer in genetically high-risk women MRI screening for breast cancer in genetically high-risk women MRI screening for breast cancer in genetically high-risk women Mundy L, Merlin T, Braunack-Mayer A, Hiller J E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mundy L, Merlin T, Braunack-Mayer A, Hiller J E. MRI (...) screening for breast cancer in genetically high-risk women. Adelaide: Adelaide Health Technology Assessment (AHTA). 2004 Authors' conclusions The current “gold standard” for breast cancer screening in Australia is mammography, which is offered free to all Australian women 40 years and over, by BreastScreen Australia. Mammography involves exposing the patient to radiation, which may represent a risk in women with a genetic pre-disposition to breast cancer. On a mammogram of normal breast tissue, fat

Health Technology Assessment (HTA) Database.2004

164. Should the French breast cancer screening programme be extended to women aged 40-49? Update

Should the French breast cancer screening programme be extended to women aged 40-49? Update Should the French breast cancer screening programme be extended to women aged 40-49? Update Should the French breast cancer screening programme be extended to women aged 40-49? Update L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES). Should the French breast cancer screening programme be extended to women aged 40-49? Update. Paris: L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) 2004: 96 Authors' objectives This study aimed to assess whether the French breast cancer screening programme should be extended to women aged 40-49 with no history of breast cancer or hereditary risk, using WHO criteria

Health Technology Assessment (HTA) Database.2004

165. Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening

Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Breast ductal lavage and fiberoptic ductoscopy for breast cancer diagnosis and screening Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Breast ductal lavage and fiberoptic ductoscopy (...) for breast cancer diagnosis and screening. Lansdale: HAYES, Inc.. Directory Publication. 2004 Authors' objectives Breast ductal lavage (DL) and fiberoptic ductoscopy (FDS) are used to evaluate patients at risk for breast cancer. DL involves collection of breast ductal epithelial cells for cytological analysis, and FDS involves direct visualization of the breast duct lining with cytology or biopsy of abnormalities. These procedures are intended to be used in conjunction with clinical breast examination

Health Technology Assessment (HTA) Database.2004

166. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening.

Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. BACKGROUND: The long term effect of mammographic service screening is not well established. We aimed to assess the long-term effect of mammographic screening on death from breast cancer, taking into account potential biases from self-selection, changes in breast cancer incidence, and classification of cause of death. METHODS: We compared deaths from breast cancer (...) diagnosed in the 20 years before screening was introduced (1958-77) with those from breast cancer diagnosed in the 20 years after the introduction of screening (1978-97) in two Swedish counties, in 210000 women aged 20-69 years. We also compared deaths from all cancers and from all causes in patients diagnosed with breast cancer in the 20 years before and after screening was introduced. In the analysis, data were stratified into age-groups invited for screening (40-69 years) and not invited (20-39 years

Lancet2003

167. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer

Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Magnetic resonance imaging of the breast in screening women considered to be at high genetic risk of breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 18(15). 2003 Authors

Health Technology Assessment (HTA) Database.2003

168. The safety net: a cost-effective approach to improving breast and cervical cancer screening

The safety net: a cost-effective approach to improving breast and cervical cancer screening The safety net: a cost-effective approach to improving breast and cervical cancer screening The safety net: a cost-effective approach to improving breast and cervical cancer screening Vogt T M, Glass A, Glasgow R E, La Chance P A, Lichtenstein E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) systems, but no intervention was delivered beyond routine system and environmental reminders. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised women unscreened for breast and cervical cancer for at least 3 years, and who had been part of the Northwest Kaiser Permanente (NWKP) managed care organisation for 3 years or more. Women in the mammography trial were aged 40 to 70 years, while women in the Pap smear study were aged

NHS Economic Evaluation Database.2003

169. Screening for prostate, breast and colorectal cancer in renal transplant recipients

Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Screening for prostate, breast and colorectal cancer in renal transplant recipients Kiberd B A, Keough-Ryan T, Clase C M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The paper examines the cost-effectiveness of specific screening for prostate, breast and colorectal cancer for patients who have received a renal transplant. Breast cancer screening comprised a mammogram every 18 months. Prostate cancer screening involved an annual digital rectal examination and a prostate specific antigen assay. The screening programme for colorectal cancer required a faecal

NHS Economic Evaluation Database.2003

170. News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer.

News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer. CONTEXT: In the late 1990s, 3 events pertaining to breast cancer prevention received considerable attention in the US news media: a National Institutes of Health (NIH) consensus panel recommended against routine screening mammography for women in their 40s (January 1997), the National Cancer Institute (NCI) subsequently reversed the recommendation (March 1997), and an NCI (...) -sponsored study demonstrated the efficacy of tamoxifen in the primary prevention of breast cancer (April 1998). OBJECTIVE: To examine how the major US news media covered the potential benefits and harms of 2 breast cancer preventive strategies. DESIGN AND SETTING: Content analysis of US news stories reporting on the breast cancer prevention events. We used Lexis-Nexis to search for print news stories in the 10 highest-circulation US newspapers and requested transcripts from 3 major television networks

JAMA2002

171. Screening for breast cancer

Screening for breast cancer Screening for breast cancer Screening for breast cancer Humphrey L, Chan B K S, Detlefsen S, Helfand M Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Humphrey L, Chan B K S, Detlefsen S, Helfand M. Screening for breast cancer. Rockville: Agency for Healthcare Research and Quality (AHRQ). Preventive Services (...) Task Force Systematic Evidence Review No. 15. 2002 Authors' objectives We conducted a systematic evidence review to update previous analyses and synthesize new data on various modes of breast cancer screening to assist the U.S. Preventive Services Task Force (USPSTF) in updating its recommendations on breast cancer screening, focusing primarily on the efficacy of screening with mammography, clinical breast exam, and breast self-exam. Authors' conclusions All of the randomized controlled trials

Health Technology Assessment (HTA) Database.2002

172. Breast Cancer: Screening

Breast Cancer: Screening Breast Cancer: Screening U.S. Preventive Services Task Force Screening for Breast Cancer Release Date: February 2002 / Summary of Recommendations The U.S. Preventive Services Task Force (USPSTF) recommends screening mammography, with or without clinical breast examination (CBE), every 1-2 years for women aged 40 and older. Rating: . Rationale: The USPSTF found fair evidence that mammography screening every 12-33 months significantly reduces mortality from breast cancer (...) . Evidence is strongest for women aged 50-69, the age group generally included in screening trials. For women aged 40-49, the evidence that screening mammography reduces mortality from breast cancer is weaker, and the absolute benefit of mammography is smaller, than it is for older women. Most, but not all, studies indicate a mortality benefit for women undergoing mammography at ages 40-49, but the delay in observed benefit in women younger than 50 makes it difficult to determine the incremental benefit

Publication 3262002

173. Customer fee and participation in breast-cancer screening.

Customer fee and participation in breast-cancer screening. Until 1997, breast screening by mammography was free for all women living in Turku, Finland. After this date, women born in certain years had to pay to be screened. We did a retrospective study, using data obtained from Statistics Finland, to ascertain whether or not the introduction of a fee affected attendance. We also assessed the effect of socioeconomic status on attendance. Our findings show that people who had to pay (...) for mammography attended less often than women who were entitled to free screening, irrespective of their socioeconomic status.

Lancet2001

174. Cochrane review on screening for breast cancer with mammography.

Cochrane review on screening for breast cancer with mammography. In 2000, we reported that there is no reliable evidence that screening for breast cancer reduces mortality. As we discuss here, a Cochrane review has now confirmed and strengthened our previous findings. The review also shows that breast-cancer mortality is a misleading outcome measure. Finally, we use data supplemental to those in the Cochrane review to show that screening leads to more aggressive treatment.

Lancet2001

175. Uptake of screening and prevention in women at very high risk of breast cancer.

Uptake of screening and prevention in women at very high risk of breast cancer. Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10 (...) % of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.

Lancet2001

176. Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer?

Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Preventive health care 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? Baxter N, Canadian Task Force on Preventive Health Care Authors' objectives The authors' stated aim was to assess the effectiveness (...) of self-examination for breast cancer screening in women. In practice, the review focused on the effectiveness of self-examination training programmes for preventing death from breast cancer. Searching MEDLINE, PREMEDLINE, CINAHL, HealthSTAR, Current Contents and the Cochrane Library were searched from 1966 to October 2000 for English language publications describing studies in humans. The keywords used were 'breast self-examination,' 'breast diseases,' 'palpation,' 'clinical trials' and 'mass

DARE.2001

177. Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review

Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review Effectiveness and cost-effectiveness of double reading of mammograms in breast cancer screening: findings of a systematic review Dinnes J, Moss S, Melia J, Blanks R, Song F, Kleijnen J Authors' objectives The authors' stated aim (...) was to compare the screening accuracy, patient outcomes, and costs of double reading versus single reading of mammograms for diagnosing breast cancer. In actuality, the authors focused largely on the cancer detection rates and recall rates. Searching The authors searched MEDLINE, CINAHL, DHSS Data, BIOSIS Previews, EMBASE, Cancerlit, databases on BIDS, Pascal, Dissertation Abstracts, the Cochrane Controlled Trials Register, SIGLE, HealthSTAR, Conference Papers Index, EconLit and the reference lists

DARE.2001

178. Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review

Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review Banks E Authors' objectives To investigate the relationship between use of hormone replacement therapy (HRT) and the risk of having breast cancer diagnosed between screenings (interval cancer (...) ) (sensitivity of screening) and the risk of false positive recall for screening following initial mammographic screening for breast cancer (specificity of screening). Searching MEDLINE and the Science Citation Index were searched up to 31 January 2000, with no language restrictions. No details of the search strategy were provided. The reference lists of identified papers were scanned and relevant (unspecified) journals were handsearched. Study selection Study designs of evaluations included in the review

DARE.2001

179. Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer

Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer Preventive health care, 2001 update: screening mammography among women aged 40 - 49 years at average risk of breast cancer Ringash J, Canadian Task Force on Preventive Health Care Authors' objectives To consider the new and updated evidence available (...) , since a review in 1994, about the effect of screening mammography on breast cancer mortality among women aged 40 to 49 years. Searching MEDLINE and Cancerlit were searched from 1966 to June 2000; the search terms were reported. Reference lists were checked for additional studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs), or meta-analyses including all eligible RCTs, were eligible for inclusion in the section on the effectiveness

DARE.2001

180. Strategies for increasing women participation in community breast cancer screening.

Strategies for increasing women participation in community breast cancer screening. BACKGROUND: Strategies for reducing breast cancer mortality in western countries have focused on screening, at least for women aged 50 to 69 years. One of the requirements of any community screening program is to achieve a high participation rate, which is related to methods of invitation. Therefore, it was decided to systematically review the scientific evidence on the different strategies aimed at improving (...) women's participation in breast cancer screening programs and activities. OBJECTIVES: To assess the effectiveness of different strategies for increasing the participation rate of women invited to community (population-based) breast cancer screening activities or mammography programs. SEARCH STRATEGY: MEDLINE (1966-2000), CENTRAL (2000), and EMBASE (1998-1999) searches for 1966 to 1999 were supplemented by reports and letters to the European Screening Breast Cancer Programs (Euref Network). SELECTION

Cochrane2001